Published August 18, 2016 | Version v1
Patent Open

INHIBITORS OF CACNA1A/ALPHA1A SUBUNIT INTERNAL RIBOSOMAL ENTRY SITE (IRES) AND METHODS OF TREATING SPINOCEREBELLAR ATAXIA TYPE 6

  • 1. University of Chicago

Contributors

Patent applicant:

Description

The disclosure provides methods of treating polyglutamine diseases, e.g., spinocerebellar ataxia Type 6, in a subject, comprising administering to the subject an IRES inhibitor in an amount effective for treating the SCA6 in the subject. Also provided herein are the IRES inhibitors, and pharmaceutical compositions comprising the same.

Files

US20160237431.pdf

Files (5.4 MB)

Name Size Download all
md5:af31e9ae2dd8c3b46e4738fc4fb7433e
5.4 MB Preview Download

Additional details

Identifiers

Patent number
US 2016/0237431 A1
Patent application number
US 201415024492 A
Other
oai:uchicago.tind.io:6696

Dates

Patent filed
2014-07-02

UChicago Information

Division(s)
Biological Sciences Division
Department(s)
Medicine, Neurology